Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia

2019 ◽

Vol 39 (6) ◽

pp. 604-610

Author(s):

Halise Devrimci-Ozguven ◽

Murad Atmaca ◽

Zeynep Baran ◽

Cengiz Cengisiz ◽

Cem Çinar ◽

...

Keyword(s):

Paliperidone Palmitate ◽

Efficacy And Safety

Download Full-text

Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia

European Neuropsychopharmacology ◽

10.1016/s0924-977x(16)31592-9 ◽

2016 ◽

Vol 26 ◽

pp. S548-S549

Author(s):

A. Savitz ◽

H. Xu ◽

S. Gopal ◽

I. Nuamah ◽

P. Ravenstijn ◽

...

Keyword(s):

Paliperidone Palmitate ◽

Efficacy And Safety

Download Full-text

Efficacy and safety of once-monthly paliperidone palmitate long-acting injection in an elderly patient with schizophrenia: Table 1

BMJ Case Reports ◽

10.1136/bcr-2015-212149 ◽

2015 ◽

pp. bcr2015212149 ◽

Cited By ~ 1

Author(s):

Palaniraj Rama Raj ◽

Matthew Lewis ◽

Stephen Macfarlane

Keyword(s):

Elderly Patient ◽

Paliperidone Palmitate ◽

Efficacy And Safety ◽

Long Acting

Download Full-text

519. Efficacy and Safety of Paliperidone Palmitate (3-Month versus 1-Month formulation) in European and Non-European Patients with Schizophrenia

Biological Psychiatry ◽

10.1016/j.biopsych.2017.02.1127 ◽

2017 ◽

Vol 81 (10) ◽

pp. S211

Author(s):

Adam Savitz ◽

Haiyan Xu ◽

Srihari Gopal ◽

Isaac Nuamah ◽

Paulien Ravenstijn ◽

...

Keyword(s):

Paliperidone Palmitate ◽

Efficacy And Safety

Download Full-text

Efficacy and Safety of Paliperidone Palmitate 3-month Formulation in Schizophrenia: a Randomized, Double-blind, Placebo-controlled Study

European Psychiatry ◽

10.1016/s0924-9338(15)30222-4 ◽

2015 ◽

Vol 30 ◽

pp. 272 ◽

Cited By ~ 2

Author(s):

J. Berwaerts ◽

Y. Liu ◽

S. Gopal ◽

I. Nuamah ◽

H. Xu ◽

...

Keyword(s):

Paliperidone Palmitate ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Neuropsychiatric Disease and Treatment ◽

10.2147/ndt.s189668 ◽

2019 ◽

Vol Volume 15 ◽

pp. 587-602 ◽

Cited By ~ 2

Author(s):

Adam J Savitz ◽

Haiyan Xu ◽

Srihari Gopal ◽

Isaac Nuamah ◽

Paulien Ravenstijn ◽

...

Keyword(s):

European Population ◽

Paliperidone Palmitate ◽

Efficacy And Safety

Download Full-text

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

Brazilian Journal of Psychiatry ◽

10.1590/1516-4446-2018-0153 ◽

2019 ◽

Vol 41 (6) ◽

pp. 499-510

Author(s):

Adam J. Savitz ◽

Haiyan Xu ◽

Srihari Gopal ◽

Isaac Nuamah ◽

Maju Mathews ◽

...

Keyword(s):

Latin American ◽

Subgroup Analysis ◽

Paliperidone Palmitate ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Large Phase

Download Full-text

Efficacy and Safety of Paliperidone Palmitate in the Treatment of Schizophrenia: A Meta-Analysis

Value in Health ◽

10.1016/j.jval.2014.08.025 ◽

2014 ◽

Vol 17 (7) ◽

pp. A722

Author(s):

Y Huang ◽

G Liu ◽

CZ Wang ◽

YH Liu

Keyword(s):

Meta Analysis ◽

Paliperidone Palmitate ◽

Efficacy And Safety

Download Full-text

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

The International Journal of Neuropsychopharmacology ◽

10.1093/ijnp/pyw018 ◽

2016 ◽

Vol 19 (7) ◽

pp. pyw018 ◽

Cited By ~ 64

Author(s):

Adam J. Savitz ◽

Haiyan Xu ◽

Srihari Gopal ◽

Isaac Nuamah ◽

Paulien Ravenstijn ◽

...

Keyword(s):

Paliperidone Palmitate ◽

Efficacy And Safety ◽

Double Blind

Download Full-text

Abstract #15: Efficacy and Safety of Long-Acting Injectable Paliperidone Palmitate Relative to Long-Acting Injectable Haloperidol, Bromperidol, and Fluphenazine Decanoate for Long-Term Treatment in Patients with Schizophrenia Using Number Needed to Treat and Number Needed to Harm

Neurotherapeutics ◽

10.1016/j.nurt.2010.06.017 ◽

2010 ◽

Vol 7 (3) ◽

pp. 333-333

Author(s):

Srihari Gopal ◽

Joris Berwaerts ◽

Isaac Nuamah ◽

Kasem Akhras ◽

Danielle Coppola ◽

...

Keyword(s):

Term Treatment ◽

Paliperidone Palmitate ◽

Number Needed To Treat ◽

Efficacy And Safety ◽

Fluphenazine Decanoate ◽

Long Term Treatment ◽

Long Acting ◽

Number Needed To Harm

Download Full-text

Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia

Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia

Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia

Efficacy and safety of once-monthly paliperidone palmitate long-acting injection in an elderly patient with schizophrenia: Table 1

519. Efficacy and Safety of Paliperidone Palmitate (3-Month versus 1-Month formulation) in European and Non-European Patients with Schizophrenia

Efficacy and Safety of Paliperidone Palmitate 3-month Formulation in Schizophrenia: a Randomized, Double-blind, Placebo-controlled Study

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies

Efficacy and Safety of Paliperidone Palmitate in the Treatment of Schizophrenia: A Meta-Analysis

Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

Abstract #15: Efficacy and Safety of Long-Acting Injectable Paliperidone Palmitate Relative to Long-Acting Injectable Haloperidol, Bromperidol, and Fluphenazine Decanoate for Long-Term Treatment in Patients with Schizophrenia Using Number Needed to Treat and Number Needed to Harm

Export Citation Format